• Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

  • Feb 5 2025
  • Length: 37 mins
  • Podcast

Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

Listen for free

View show details

  • Summary

  • From high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients.

    Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp
    📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4
    📖Paperback: https://amzn.to/4gAXrz4

    💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
    USE CODE "OTP10" to save 10%.

    SOCIALS:
    📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx
    🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1
    👾: https://discord.gg/ZHeUh7WV
    📺: https://youtube.com/@ManOnTheMounjaro?feature=shared
    ❌: https://x.com/manonthepen?s=21
    💻: https://www.onthepen.com
    Show More Show Less
Show More Show Less

What listeners say about Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.